On the Radar…

GlobeImmune, Inc announced data from a Phase 2b trial of Tarmogen GI-5005 in the treatment of patients with hepatitis C. In the trial, 74% of interferon-naïve patients receiving GI-5005 in combination with standard of care (pegylated interferon plus ribavirin) showed end of treatment response (at 48 weeks) compared with 59% receiving standard of care alone. GlobeImmune had previously released encouraging results from this trial in April when it reported that patients in the combination arm had shown an 8-12% greater early virologic repsponse rate than patients receiving standard of care alone after 12 weeks of treatment. The trial evaluated 140 patients with chronic genotype 1 hepatitis C infection who were either treatment naïve or prior non-responders. The new data will be presented today at the annual meeting of the American Association for the Study of Liver Diseases. Based in Louisville, Colorado, GlobeImmune is developing Tarmogens, genetically modified yeast designed to express specific proteins, as treatments for infectious diseases and cancer.